Cybin Inc. (CYBN): Price and Financial Metrics
CYBN Price/Volume Stats
| Current price | $0.36 | 52-week high | $0.74 |
| Prev. close | $0.36 | 52-week low | $0.21 |
| Day low | $0.34 | Volume | 3,514,300 |
| Day high | $0.36 | Avg. volume | 5,116,370 |
| 50-day MA | $0.39 | Dividend yield | N/A |
| 200-day MA | $0.42 | Market Cap | 145.85M |
CYBN Stock Price Chart Interactive Chart >
Cybin Inc. (CYBN) Company Bio
Cybin, Inc. is a biotechnology company that focuses on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. It operates through the following segments: Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Latest CYBN News From Around the Web
Below are the latest news stories about CYBIN INC that investors may wish to consider to help them evaluate CYBN as an investment opportunity.
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy PotentialThe increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. |
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog ProgramTORONTO, December 06, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office ("USPTO") has granted U.S. patent 11,834,410 in support of its CYB003 program. |
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline ResultsTORONTO, December 05, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the presentation of four posters at the American College of Neuropsychopharmacology ("ACNP") annual meeting taking place December 3-6, 2023, in Tampa, Florida. The data presented include topline data from its |
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg DosesTORONTO, November 30, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder ("MDD"). |
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York CityTORONTO, November 20, 2023--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it will discuss its topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder, as part of an R&D investor briefing featuring a ke |
CYBN Price Returns
| 1-mo | -16.12% |
| 3-mo | -2.70% |
| 6-mo | -41.84% |
| 1-year | 14.98% |
| 3-year | -76.00% |
| 5-year | N/A |
| YTD | -12.20% |
| 2023 | 38.00% |
| 2022 | -75.24% |
| 2021 | -19.46% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...